BAYER Supplement: Making Time for Change

BAYER Supplement: Making Time for Change

Chairman’s introduction:
Macular degeneration and retinal disease, a major and growing worldwide health challenge

Prof Andrew Lotery, honorary consultant ophthalmologist, University Hospital Southampton and professor of ophthalmology, University of Southampton, chaired Bayer’s Satellite Symposium ‘Making time for change: using aflibercept solution for injection in a clinical setting’, Retina Day, the Royal College of Ophthalmologists Annual Congress, held 19
May 2014, Birmingham, UK.


“Age-related macular degeneration is the commonest cause of blindness in the western world,” explained Prof Lotery.1 “It affects up to 25 million people worldwide and up to 30,000 people are diagnosed with neovascular AMD each year in the United Kingdom alone.1,2 Studies evaluating age-specific prevalence of AMD show a strong rise with age,
and overall prevalence rates in the age groups 65-74 years and 75-84 years of 20 and 35 per cent, respectively.3 So there’s an escalating epidemic as the population ages and AMD is a major public health problem.”  Download Supplement - click here

Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...